Inhibition of prostate cancer RM1 cell growth in vitro by hydroxyapatite nanoparticle‑delivered short hairpin RNAs against Stat3

Liang,Zuowen; Wang,Hongliang; Guo,Baofeng; Li,Fubiao; Liu,Jinsha; Liu,Zhewen; Xu,Libo; Yun,Wenjing; Zhao,Xuejian; Zhang,Ling

doi:10.3892/mmr.2017.6583

Inhibition of prostate cancer RM1 cell growth in vitro by hydroxyapatite nanoparticle‑delivered short hairpin RNAs against Stat3

Authors:
- Zuowen Liang
- Hongliang Wang
- Baofeng Guo
- Fubiao Li
- Jinsha Liu
- Zhewen Liu
- Libo Xu
- Wenjing Yun
- Xuejian Zhao
- Ling Zhang
View Affiliations

Affiliations: Department of Andrology, First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China, Department of Plastic Surgery, China‑Japan Union Hospital of Jilin University, Changchun, Jilin 130031, P.R. China, Department of Pathophysiology, College of Basic Medicine, Jilin University, Changchun, Jilin 130021, P.R. China
Published online on: May 16, 2017 https://doi.org/10.3892/mmr.2017.6583
Pages: 459-465

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study investigated the effect of signal transducer and activator of transcription 3 (Stat3) interference on RM1 prostate cancer cell viability in vitro, using plasmid‑based Stat3 specific short hairpin RNA (sh‑Stat3) delivered by hydroxyapatite nanoparticles (HAP). HAP carrying sh‑Stat3 plasmids were transfected into tumor cells. MTT assays were used to measure RM1 cell viability 24 and 48 h following transfection, and the apoptosis rate and cell cycle phase distribution were determined by flow cytometry. Stat3 mRNA expression levels were measured by reverse transcription‑quantitative polymerase chain reaction and Stat3, Cyclin D1, B cell lymphoma 2 apoptosis regulator (Bcl‑2), vascular endothelial growth factor (VEGF), Bcl‑2 associated X apoptosis regulator (Bax) and cleaved‑caspase‑3 protein expression levels were detected using western blot analysis. The results demonstrated that HAP‑delivered sh‑Stat3 significantly decreased RM1 cell viability through the promotion of cell cycle arrest and apoptosis. Stat3 mRNA and protein expression levels were significantly downregulated in RM1 cells. Bcl‑2, VEGF and Cyclin D1 were also significantly downregulated, but cleaved‑caspase‑3 and Bax mRNA and protein expression levels were significantly upregulated. HAP‑delivered sh‑Stat3 decreased RM1 cell viability in vitro, and HAP assisted plasmid‑based delivery of shRNA into tumor cells. The present results suggest that HAP may be a useful method for successful shRNA delivery into tumors.

View Figures

View References

1	Do TN, Lee WH, Loo CY, Zavgorodniy AV and Rohanizadeh R: Hydroxyapatite nanoparticles as vectors for gene delivery. Ther Deliv. 3:623–632. 2012. View Article : Google Scholar : PubMed/NCBI
2	Bose S and Tarafder S: Calcium phosphate ceramic systems in growth factor and drug delivery for bone tissue engineering: A review. Acta Biomater. 8:1401–1421. 2012. View Article : Google Scholar : PubMed/NCBI
3	Olton D, Li J, Wilson ME, Rogers T, Close J, Huang L, Kumta PN and Sfeir C: Nanostructured calcium phosphates (NanoCaPs) for non-viral gene delivery: Influence of the synthesis parameters on transfection efficiency. Biomaterials. 28:1267–1279. 2007. View Article : Google Scholar : PubMed/NCBI
4	Ginebra MP, Canal C, Espanol M, Pastorino D and Montufar EB: Calcium phosphate cements as drug delivery materials. Adv Drug Deliv Rev. 64:1090–1110. 2012. View Article : Google Scholar : PubMed/NCBI
5	Loo SC, Moore T, Banik B and Alexis F: Biomedical applications of hydroxyapatite nanoparticles. Curr Pharm Biotechnol. 11:333–342. 2010. View Article : Google Scholar : PubMed/NCBI
6	Chen L, McCrate JM, Lee JC and Li H: The role of surface charge on the uptake and biocompatibility of hydroxyapatite nanoparticles with osteoblast cells. Nanotechnology. 22:1057082011. View Article : Google Scholar : PubMed/NCBI
7	Zakaria SM, Zein Sharif SH, Othman MR, Yang F and Jansen JA: Nanophase hydroxyapatite as a biomaterial in advanced hard tissue engineering: A review. Tissue Eng Part B Rev. 19:431–441. 2013. View Article : Google Scholar : PubMed/NCBI
8	Tan K, Cheang P, Ho IA, Lam PY and Hui KM: Nanosized bioceramic particles could function as efficient gene delivery vehicles with target specificity for the spleen. Gene Ther. 14:828–835. 2007. View Article : Google Scholar : PubMed/NCBI
9	Sun H, Jiang M and Zhu SH: In vitro and in vivo studies on hydroxyapatite nanoparticles as a novel vector for inner ear gene therapy. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 43:51–57. 2008.(In Chinese). PubMed/NCBI
10	Wu X, Ding D, Jiang H, Xing X, Huang S, Liu H, Chen Z and Sun H: Transfection using hydroxyapatite nanoparticles in the inner ear via an intact round window membrane in chinchilla. J Nanopart Res. 14:7082012. View Article : Google Scholar
11	Yan-Zhong Z, Yan-Yan H, Jun Z, Shai-Hong Z, Zhi-You L and Ke-Chao Z: Characteristics of functionalized nano-hydroxyapatite and internalization by human epithelial cell. Nanoscale Res Lett. 6:6002011. View Article : Google Scholar : PubMed/NCBI
12	Liang ZW, Guo BF, Li Y, Li XJ, Li X, Zhao LJ, Gao LF, Yu H, Zhao XJ, Zhang L and Yang BX: Plasmid-based Stat3 siRNA delivered by hydroxyapatite nanoparticles suppresses mouse prostate tumour growth in vivo. Asian J Androl. 13:481–486. 2011. View Article : Google Scholar : PubMed/NCBI
13	Gao L, Zhang L, Hu J, Li F, Shao Y, Zhao D, Kalvakolanu DV, Kopecko DJ, Zhao X and Xu DQ: Down-regulation of signal transducer and activator of transcription 3 expression using vector-based small interfering RNAs suppresses growth of human prostate tumor in vivo. Clin Cancer Res. 11:6333–6341. 2005. View Article : Google Scholar : PubMed/NCBI
14	Yamada M, Ueno T, Tsukimura N, Ikeda T, Nakagawa K, Hori N, Suzuki T and Ogawa T: Bone integration capability of nanopolymorphic crystalline hydroxyapatite coated on titanium implants. Int J Nanomedicine. 7:859–873. 2012.PubMed/NCBI
15	Fernandez JM, Molinuevo MS, Cortizo MS and Cortizo AM: Development of an osteoconductive PCL-PDIPF-hydroxyapatite composite scaffold for bone tissue engineering. J Tissue Eng Regen Med. 5:e126–e135. 2011. View Article : Google Scholar : PubMed/NCBI
16	Ye F, Guo H, Zhang H and He X: Polymeric micelle-templated synthesis of hydroxyapatite hollow nanoparticles for a drug delivery system. Acta Biomater. 6:2212–2218. 2010. View Article : Google Scholar : PubMed/NCBI
17	Liu H, Xi P, Xie G, Chen F, Li Z, Bai D and Zeng Z: Biocompatible hydroxyapatite nanoparticles as a redox luminescence switch. J Biol Inorg Chem. 16:1135–1140. 2011. View Article : Google Scholar : PubMed/NCBI
18	Barghi L, Asgari D, Barar J, Nakhlband A and Valizadeh H: Synthesis, characterization and in vitro anti-tumoral evaluation of Erlotinib-PCEC nanoparticles. Asian Pac J Cancer Prev. 15:10281–10287. 2014. View Article : Google Scholar : PubMed/NCBI
19	Xu J, Xu P, Li Z, Huang J and Yang Z: Oxidative stress and apoptosis induced by hydroxyapatite nanoparticles in C6 cells. J Biomed Mater Res A. 100:738–745. 2012. View Article : Google Scholar : PubMed/NCBI
20	Zhang L, Gao L, Li Y, Lin G, Shao Y, Ji K, Yu H, Hu J, Kalvakolanu DV, Kopecko DJ, et al: Effects of plasmid-based Stat3-specific short hairpin RNA and GRIM-19 on PC-3M tumor cell growth. Clin Cancer Res. 14:559–568. 2008. View Article : Google Scholar : PubMed/NCBI
21	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
22	Barton BE, Karras JG, Murphy TF, Barton A and Huang HF: Signal transducer and activator of transcription 3 (STAT3) activation in prostate cancer: Direct STAT3 inhibition induces apoptosis in prostate cancer lines. Mol Cancer Ther. 3:11–20. 2004. View Article : Google Scholar : PubMed/NCBI
23	Da Silveira RA, Hermes CL, Almeida TC, Bochi GV, De Bona KS, Moretto MB and Moresco RN: Ischemia-modified albumin and inflammatory biomarkers in patients with prostate cancer. Clin Lab. 60:1703–1708. 2014. View Article : Google Scholar : PubMed/NCBI
24	Dumache R, Puiu M, Motoc M, Vernic C and Dumitrascu V: Prostate cancer molecular detection in plasma samples by glutathione S-transferase P1 (GSTP1) methylation analysis. Clin Lab. 60:847–852. 2014. View Article : Google Scholar : PubMed/NCBI
25	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
26	Aneknan P, Kukongviriyapan V, Prawan A, Kongpetch S, Sripa B and Senggunprai L: Luteolin arrests cell cycling, induces apoptosis and inhibits the JAK/STAT3 pathway in human cholangiocarcinoma cells. Asian Pac J Cancer Prev. 15:5071–5076. 2014. View Article : Google Scholar : PubMed/NCBI
27	Siveen KS, Sikka S, Surana R, Dai X, Zhang J, Kumar AP, Tan BK, Sethi G and Bishayee A: Targeting the STAT3 signaling pathway in cancer: Role of synthetic and natural inhibitors. Biochim Biophys Acta. 1845:136–154. 2014.PubMed/NCBI
28	Han Z, Wang X, Ma L, Chen L, Xiao M, Huang L, Cao Y, Bai J, Ma D, Zhou J and Hong Z: Inhibition of STAT3 signaling targets both tumor-initiating and differentiated cell populations in prostate cancer. Oncotarget. 5:8416–8428. 2014. View Article : Google Scholar : PubMed/NCBI
29	Kim WJ and Kim SW: Efficient siRNA delivery with non-viral polymeric vehicles. Pharm Res. 26:657–666. 2009. View Article : Google Scholar : PubMed/NCBI
30	Zhu SH, Huang BY, Zhou KC, Huang SP, Liu F, Li YM, Xue ZG and Long ZG: Hydroxyapatite nanoparticles as a novel gene carrier. J Nanopart Res. 6:307–311. 2004. View Article : Google Scholar
31	Lim SL, Park SY, Kang S, Park D, Kim SH, Um JY, Jang HJ, Lee JH, Jeong CH, Jang JH, et al: Morusin induces cell death through inactivating STAT3 signaling in prostate cancer cells. Am J Cancer Res. 5:289–299. 2014.PubMed/NCBI
32	Zhou Y, Tian L, Zhang YC, Guo BF and Zhou QW: Apoptotic effects of psiRNA-STAT3 on 4T1 breast cancer cells in vitro. Asian Pac J Cancer Prev. 15:6977–6982. 2014. View Article : Google Scholar : PubMed/NCBI
33	Chen Z and Han ZC: STAT3: A critical transcription activator in angiogenesis. Med Res Rev. 28:185–200. 2008. View Article : Google Scholar : PubMed/NCBI